INSIGHT
A blood-test-selected trial testing whether matching the drug to the specific resistance mutation beats the standard second-line drug.
Built on INTRIGUE's exploratory finding (PFS 14.2 vs 1.5 months in this genotype). Small mutation-selected phase 3; reported positive for PFS per 2026 company and congress reports. The first ctDNA-genotype-directed randomised trial in GIST.
Setting
Second-line GIST with KIT exon 11 + exon 17/18 mutations (ctDNA-selected): ripretinib vs sunitinib
Phase
Phase 3
Sponsor
Deciphera / Ono
Registry
Headline result
PFS favouring ripretinib in the ctDNA-defined subgroup (2026).
Reported
2026
Enrolled
54
Pages like this
not linked directly; found by shared links- TrialINVICTUS
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- TrialSSGXVIII/AIO (adjuvant imatinib in GIST)
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- CompanyDeciphera Pharmaceuticals (Ono)
- TargetPDGFRA
Shares Ripretinib, KIT, Sarcomas (soft tissue, bone, GIST).
- PersonCharles D. Blanke
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- ProductPexidartinib
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- ProductPazopanib
Shares KIT, Sarcomas (soft tissue, bone, GIST).
- IdeaWhole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome
Shares Sarcomas (soft tissue, bone, GIST), Liquid biopsy (ctDNA).